Most Popular Stories
- Lawsuits starting to mount against Goldman Sachs
- What to make of Goldman Sachs' move into derivatives clearing?
- Citigroup explores Volcker Rule options
- SEC seeks comments on fiduciary standard vs. suitability
- Goldman Sachs' hedges on AIG exposure debated
- Tabb Group: Buy-side continues to embrace algorithms
Events
Sponsored Links
FEATURES >> Where are they now? The whistleblowers edition | Q2 Earnings
TOPICS >> Hedge Funds | Derivatives Trading | Regulatory News | Top Banks: GS C BAC JPM WFC MS
Latest News
Free Newsletter
FierceFinance is the financial services daily monitor, with news covering the banking industry, asset management, capital markets and SEC regulations. Sign up today!
We never sell or give away your contact information. Our reader's trust comes first.
Why Lehman Brothers really went belly up
"The Wall Street equivalent of a coroner's report." That's what the New York Times calls the 2,200 page tome delivered by bank examiner Anton Valukas about the demise of Lehman Brothers (Lehman Brothers news). It's something of a bombshell and the legal ramifications, at least at the civil level, may well be severe, as it accuses the likes of Dick Fuld (Richard Fuld news) with "manipulation" and "at least grossly negligent."
The reports found that Lehman "used what amounted to financial engineering to temporarily shuffle $50 billion of troubled assets off its books in the months before its collapse in September 2008 to conceal its dependence on leverage, or borrowed money. Senior Lehman executives, as well as the bank's accountants at Ernst & Young, were aware of the moves." Fuld signed off on them. In addition, JPMorgan Chase (NYSE: JPM) and Citigroup (NYSE: C) contributed to the liquidity crunch at Lehman by asking for more collateral.
The report details the bank's "Repo 105" ploy, the main method of masking the troubled securities. Fuld's lawyer told the paper he "did not know what those transactions were--he didn't structure or negotiate them, nor was he aware of their accounting treatment." Another executive wrote this in email about Repo 105: "I am very aware...it is another drug we're on."
For more:
- here's the article
Related Articles:
Where in the world is Erin Callan?
Another bad bet by Lehman Brothers: Art?
JPMorgan at risk in Lehman controversy?
Paulson's real mistake
Related Stories
- Lehman investigation focuses on Erin Callan
- Ira Sohn conference fetes top managers
- Will regulators aim next at window dressing?
- Likelihood of criminal prosecutions on decline?
- Wall Street firms face GIC contract probe; mystery witness emerges
- Lehman Brothers lawyer: Fuld understated his pay
- At Goldman Sachs, bankers vs. traders lines hardening?
- Can quarterly window dressing by big banks be stopped?
- Big day approaches for Lehman Brothers
- What to make of Lehman's good bank/bad bank idea
Comments
Post new comment
Home
| Subscribe | Advertise | Mobile Edition | RSS |
Privacy
| Site MapTHE FIERCEMARKETS NETWORKFierceFinance | FierceFinanceIT | FierceComplianceIT | FierceHealthcare | FierceHealthFinance | FierceHealthIT | Hospital Impact | FierceMobileHealthcare | FierceHealthPayer | FiercePracticeManagement | FierceCIO | FierceCIO:TechWatch | FierceContentManagement | FierceMobileIT | FierceGovernmentIT | FierceBiotech | FierceBiotech Research | FiercePharma | FierceVaccines | FierceBiotechIT | FiercePharma Manufacturing | FierceMedicalDevices | FierceDrugDelivery | FierceIPTV | FierceOnlineVideo | FierceTelecom | FierceVoIP | FierceBroadbandWireless | FierceDeveloper | FierceMobileContent | FierceWireless | FierceWireless:Europe | FierceCable© 2010 FierceMarkets. All rights reserved. |
![]() |



